Assembly Biosciences (NASDAQ:ASMB) released its earnings results on Thursday. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.14, MarketWatch Earnings reports. The business had revenue of $4.29 million for the quarter, compared to the consensus estimate of $3.21 million. Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%.
Shares of Assembly Biosciences stock traded down $2.19 during trading on Friday, hitting $23.40. The stock had a trading volume of 193,657 shares, compared to its average volume of 168,602. The company has a market cap of $585.27 million, a P/E ratio of -9.71 and a beta of 1.43. Assembly Biosciences has a 1 year low of $20.61 and a 1 year high of $67.36.
Several research analysts have recently weighed in on the stock. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 3rd. Chardan Capital reissued a “neutral” rating on shares of Assembly Biosciences in a research report on Sunday, October 28th. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Monday, October 8th. Finally, ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $62.60.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
See Also: How to Use the New Google Finance Tool
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.